Harpoon is well-positioned to play a significant role in immuno-oncology, Arix said
Global healthcare and life sciences company () said Harpoon Therapeutics, one of its portfolio companies, has completed its flotation on NASDAQ.
Harpoon, a clinical-stage immunotherapy company developing a novel class of T cell engagers, completed an initial public offering (IPO) of 5.4mln shares at US$14 a shot, raising US$75.6mln.
Arix retains a stake of 12.1% in Harpoon, which was valued at £31.3mln at the close of business on 13 February 2019, representing a gain of £12.1mln on total cash invested in Harpoon by Arix.
Arix has a market capitalisation of around £220mln.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE